ARKADY NISMAN, PHARMD

home / authors / arkady-nisman-pharmd

Articles

A Further Look at Rational Polytherapy in Patients With Uncontrolled Epilepsy: Insights From a Post hoc Analysis of Adjunctive Cenobamate

LOUIS FERRARI, MBA, RPH;ARKADY NISMAN, PHARMD

December 21st 2021

Increasing Awareness and Counseling on the Importance of Titration Schedules

Lou Ferrari, RPh, MBA;ARKADY NISMAN, PHARMD;Rolando J. Veloso, PharmD

March 5th 2021

The Evolving Epilepsy Treatment Spectrum: A Review of Antiepileptic Drugs in Late Development

BY LOUIS FERRARI, MBA, RPH;JEONG WOO CHO, PHD;ARKADY NISMAN, PHARMD

October 29th 2019

Given the relatively static rate of seizure freedom with the current antiepileptic drug (AED) armamentarium, a need remains for the development of new compounds to help enable more patients achieve seizure freedom. Fortunately, several investigational therapeutic agents and delivery systems are in phase 3 development, which are being investigated for the treatment of orphan diseases and focal-onset and generalized-onset seizures.

Published: October 23rd 2024 | Updated: October 24th 2024

What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders